Overactive Bladder Category Switch Prospects Questioned By Indevus
This article was originally published in The Tan Sheet
Executive Summary
Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call
You may also be interested in...
Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.
Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.
Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.